Metro International Biotech Announces Initial Dosing in the First Cohort of a Phase 1a Clinical Trial of its Novel NAD Booster MIB-725
WORCESTER, Mass.--(BUSINESS WIRE)--Metro International Biotech, LLC (MetroBiotech), an EdenRoc Sciences company that is developing more effective treatments of age-related diseases, today announced that the first patients in Cohort 1 of its Phase 1a clinical trial of MIB-725 have received their initial doses.
MIB-725 is a new, proprietary investigational drug that has been demonstrated in preclinical studies to be a potent NAD precursor or booster.
MIB-725 is a new, proprietary investigational drug that has been demonstrated in preclinical studies to be a potent NAD precursor or booster. In this Phase 1a single ascending dose study, the safety, pharmacokinetics, metabolism and effect of MIB-725 on circulating NAD levels will be determined. Later trials will investigate MIB-725's efficacy in treating chronic kidney disease associated with aging.
In the initial four of eight patients to be dosed in the first cohort, no dose-limiting toxicities were observed. Once the remaining patients are dosed in the cohort, subsequent doses will be gradually increased. If this single dose trial is concluded successfully, a follow-on trial with multiple dosing (Phase 1b) will be run at the same site by the investigators.
"Commencement of Phase 1 testing of our novel NAD booster is a key step in our vision of developing the potential of a family of NAD precursor compounds optimized for particular therapeutic indications,' said David Livingston, Ph.D., president and chief scientific officer of MetroBiotech. 'The current single ascending dose trial of MIB-725 will create our first safety, PK/PD and metabolic database for this unique molecule, and is an important milestone in our company's clinical development program. We believe this trial will inform the compound expansion stage of our ongoing clinical trials and may allow us to obtain initial evidence of clinical activity as the program continues to advance."
About MIB-725
MIB-725 is the second MetroBiotech therapeutic candidate that targets diseases of aging such as kidney disease, neurodegenerative disease, and muscle disorders. A robust Phase 2 clinical program is ongoing for MetroBiotech's initial investigational drug MIB-626. Both MIB-626 and MIB-725 have shown pharmacological activity in a variety of preclinical models that demonstrated NAD boosting effects, as well as suppression of pancreatitis, acute kidney injury, and rare mitochondrial disease-associated cardiovascular function. These two compounds are differentially used in NAD-elevating pathways in mammals.
About Metro International Biotech, LLC
MetroBiotech, an EdenRoc Sciences company, is a clinical-stage metabolism company focused on treating diseases of aging such a muscle weakness, kidney diseases, neurodegenerative diseases, and cancer. MetroBiotech is committed to treating such diseases with NAD boosters of high safety that can effectively target different organs. Through intelligent medicinal chemistry design and process development, the company is producing pharmaceutical-grade NAD boosters at the scale required for early- and late-stage clinical testing. The ongoing independent Phase 1 clinical trials of MIB-725, as well as the Phase 2 clinical trials of MIB-626, are all being run under INDs cleared by FDA. MetroBiotech's commitment to FDA standards for investigational drugs make the company unique in the NAD booster space. Learn more at metrobiotech.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing, conduct and results of the Phase 1 clinical trial, statements about microRNAs and their involvement in cancer, and statements concerning the therapeutic potential of MetroBiotech's MIB-725. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with MetroBiotech's pre-clinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with MetroBiotech's financial condition and its need to obtain additional funding to support its business activities, including MetroBiotech's ability to continue as a going concern; risks associated with the timing and outcome of MetroBiotech's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with MetroBiotech's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with MetroBiotech's dependence on third parties; and risks associated with geopolitical events and pandemics, including the COVID-19 coronavirus and military actions. All information in this press release is as of the date of this release; MetroBiotech undertakes no duty to update this information unless required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Black & Veatch Participates in Industry Dialogues, Identifies Viable Pathways to Deliver Asia's Energy Transition at Energy Asia 2025
KUALA LUMPUR, Malaysia, June 10, 2025--(BUSINESS WIRE)--Black & Veatch, a global leader in human critical infrastructure solutions, will share ways to adapt international best practices to accelerate Southeast Asia's energy transition at the Energy Asia 2025 conference, taking place June 16-18 at the Kuala Lumpur Convention Center here. "As geopolitical tensions rise and extreme heat waves become more prolonged, Malaysia and its Southeast Asian neighbors need energy transition solutions that will meet their economic and environmental targets. "Black & Veatch is committed to drawing on its extensive sustainable infrastructure experience to help the region meet its growing energy demands with low and no-carbon energy sources," said Jerin Raj, managing director, Asia Pacific, Black & Veatch. Deep collaborations with industry leaders from energy and other sectors, and knowledge transfer are part of that commitment. At the conference in Malaysia, Anand Pattani, vice president and managing director, International Energy Majors, Black & Veatch, will discuss how traditional refiners can adapt to remain competitive in a low-carbon world and the pathways most viable for the refining sector. Pattani will propose global strategies that can be adapted to overcome technical, regulatory, and financial barriers. Aligning with Malaysia's priorities to reduce carbon footprints, optimize resource efficiency, and promote sustainable development, Black & Veatch has supported power projects in Malaysia since the 1990s, from strategic decision-making to financial and resource commitments, implementation and execution. About Black & Veatch Black & Veatch is a 100-percent employee-owned global engineering, procurement, consulting and construction company with more than 100-years of innovation in sustainable infrastructure. Since 1915, we have helped our clients improve the lives of people around the world by addressing the resilience and reliability of our most important infrastructure and energy assets. Follow us on and on LinkedIn, Facebook, X (Twitter) and Instagram. View source version on Contacts Media Contact Information: EMILY CHIA | +65 6335 6623 | Media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Black & Veatch Participates in Industry Dialogues, Identifies Viable Pathways to Deliver Asia's Energy Transition at Energy Asia 2025
KUALA LUMPUR, Malaysia--(BUSINESS WIRE)-- Black & Veatch, a global leader in human critical infrastructure solutions, will share ways to adapt international best practices to accelerate Southeast Asia's energy transition at the Energy Asia 2025 conference, taking place June 16-18 at the Kuala Lumpur Convention Center here. 'As geopolitical tensions rise and extreme heat waves become more prolonged, Malaysia and its Southeast Asian neighbors need energy transition solutions that will meet their economic and environmental targets. 'Black & Veatch is committed to drawing on its extensive sustainable infrastructure experience to help the region meet its growing energy demands with low and no-carbon energy sources,' said Jerin Raj, managing director, Asia Pacific, Black & Veatch. Deep collaborations with industry leaders from energy and other sectors, and knowledge transfer are part of that commitment. At the conference in Malaysia, Anand Pattani, vice president and managing director, International Energy Majors, Black & Veatch, will discuss how traditional refiners can adapt to remain competitive in a low-carbon world and the pathways most viable for the refining sector. Pattani will propose global strategies that can be adapted to overcome technical, regulatory, and financial barriers. Aligning with Malaysia's priorities to reduce carbon footprints, optimize resource efficiency, and promote sustainable development, Black & Veatch has supported power projects in Malaysia since the 1990s, from strategic decision-making to financial and resource commitments, implementation and execution. About Black & Veatch Black & Veatch is a 100-percent employee-owned global engineering, procurement, consulting and construction company with more than 100-years of innovation in sustainable infrastructure. Since 1915, we have helped our clients improve the lives of people around the world by addressing the resilience and reliability of our most important infrastructure and energy assets. Follow us on and on LinkedIn, Facebook, X (Twitter) and Instagram.
Business Wire
an hour ago
- Business Wire
Mitsubishi Electric's ME Innovation Fund Invests in Carbon Credit Monitoring Startup Archeda
TOKYO--(BUSINESS WIRE)-- Mitsubishi Electric Corporation (TOKYO: 6503) announced today that its ME Innovation Fund has invested in Archeda, Inc., a Japan-based startup that uses satellite data to develop and provide monitoring and analysis tools for carbon credits. The carbon credit system enables companies and other entities to buy and sell greenhouse gas-reduction outcomes (reduced or sequestered volumes) as emissions-allowance credits. This is the eleventh investment that the fund has made to date. As global efforts toward achieving carbon neutrality gain momentum, carbon offsetting has emerged as an effective strategy. Under this concept, companies, etc. strive to reduce their greenhouse gas emissions as much as possible and then compensate for any remaining emissions by investing in sustainable projects that reduce or sequester an equivalent amount of greenhouse gases. In Japan, an increasingly active market is developing for nature-based carbon credits, including activities to manage, conserve and protect the natural environment. The demand for carbon offsets and nature-based credits in Japan is expected to rise significantly with the planned launch of a national emissions trading scheme in fiscal 2027. The scheme, which will apply to companies that emit over 100,000 tons of CO 2 annually, will set a cap on each company's CO 2 emissions and allow them to trade surplus or deficit emissions allowances. However, challenges remain, such as the lack of clarity regarding how credits will be issued, highlighting the urgent need for mechanisms to ensure the trustworthiness of carbon credits.
